# Jelle Wesseling

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jelle-wesseling/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,872 |
| Field | Breast Cancer Treatment Studies |
| h-index | 73 |
| i10-index | 253 |
| Last Known Institution | Leiden University Medical Center |
| OpenAlex ID | https://openalex.org/A5020517461 |
| ORCID iD | 0000-0002-8940-2676 |
| Works | 698 |

## Researcher papers

- [Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies](https://scholariq.org/papers/subtyping-of-breast-cancer-by-immunohistochemistry-to-investigate-a-relationship/)
- [Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma](https://scholariq.org/papers/reversible-and-adaptive-resistance-to-braf-v600e-inhibition-in-melanoma/)
- [Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.](https://scholariq.org/papers/episialin-muc1-overexpression-inhibits-integrin-mediated-cell-adhesion-to/)
- [Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer](https://scholariq.org/papers/identification-of-ten-variants-associated-with-risk-of-estrogen-receptor/)
- [Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial](https://scholariq.org/papers/neoadjuvant-chemotherapy-with-or-without-anthracyclines-in-the-presence-of-dual/)
- [Personalized early detection and prevention of breast cancer: ENVISION consensus statement](https://scholariq.org/papers/personalized-early-detection-and-prevention-of-breast-cancer-envision-consensus/)
- [Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients](https://scholariq.org/papers/marking-axillary-lymph-nodes-with-radioactive-iodine-seeds-for-axillary-staging/)
- [Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study](https://scholariq.org/papers/feasibility-of-a-prospective-randomised-open-label-international-multicentre/)
- [A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.](https://scholariq.org/papers/a-mechanism-for-inhibition-of-e-cadherin-mediated-cell-cell-adhesion-by-the/)
- [w4200350191](https://scholariq.org/papers/w4200350191/)
- [Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)](https://scholariq.org/papers/use-of-70-gene-signature-to-predict-prognosis-of-patients-with-node-negative/)
- [Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study](https://scholariq.org/papers/association-of-dcis-size-and-margin-status-with-risk-of-developing-breast-cancer/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Leiden University Medical Center](https://scholariq.org/institutions/leiden-university-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.